Prothena Corporation plc develops investigational therapeutics built on protein dysregulation expertise for neurodegenerative and rare peripheral amyloid diseases. Company news commonly covers clinical and partner updates for programs such as prasinezumab in Parkinson’s disease, coramitug in ATTR amyloidosis with cardiomyopathy, BMS-986446 in Alzheimer’s disease, PRX019, and CYTOPE-based research.
Updates also include financial results, cash guidance, collaboration revenue and milestone payments from strategic partners, regulatory designations, share repurchase activity, shareholder capital actions, and leadership or governance changes.
Prothena (NASDAQ:PRTA) announced that Novo Nordisk will advance coramitug (formerly PRX004) into Phase 3 development for ATTR amyloidosis with cardiomyopathy (ATTR-CM) in 2025. Coramitug, a potential first-in-class amyloid depleter antibody, was initially developed by Prothena and acquired by Novo Nordisk in July 2021.
Under the agreement terms, Prothena is eligible to receive up to $1.2 billion in clinical development and sales milestones, including $100 million earned to date. The company will earn an additional milestone payment when prespecified enrollment criteria are met in the Phase 3 trial.
Prothena (NASDAQ:PRTA) reported Q2 2025 financial results and business updates. Key highlights include: Roche's advancement of prasinezumab into Phase 3 for early-stage Parkinson's disease by end-2025, with potential peak sales over $3 billion. The company reported a net loss of $125.8 million for Q2 2025, including $32.6 million in restructuring charges.
Financial position shows $372.3 million in cash as of June 30, 2025. The company plans to hold an EGM by year-end to propose a share capital reduction for potential share redemption. Notable pipeline developments include upcoming PRX012 Phase 1 data for Alzheimer's disease in August 2025 and potential milestone payments of up to $105 million in 2026 from partnerships with Novo Nordisk and Bristol Myers Squibb.
[ "Strong cash position of $372.3 million with no debt", "Potential milestone payments up to $105 million in 2026 from partnerships", "Prasinezumab advancing to Phase 3 with potential peak sales over $3 billion", "Multiple clinical trial catalysts expected in 2025-2026", "FDA Fast Track designation granted for PRX012 and PRX123 for Alzheimer's disease" ]Prothena (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on protein dysregulation therapeutics, has scheduled the release of its Q2 and H1 2025 financial results for Monday, August 4, 2025, following the U.S. market close. The company has indicated that it will maintain its standard practice of not holding a conference call to discuss the results.
Prothena Corporation (NASDAQ: PRTA), a late-stage clinical biotechnology company focused on protein dysregulation therapeutics, has scheduled the release of its first quarter 2025 financial results for Thursday, May 8, 2025, after U.S. financial markets close. The company has indicated that, following their usual practice, they will not hold a conference call to discuss the results.
Prothena (PRTA) reported its Q4 and full year 2024 financial results. The company recorded a net loss of $58.0 million in Q4 and $122.3 million for the full year 2024. Total revenue was $2.1 million in Q4 and $135.2 million for the full year 2024.
Key financial metrics include:
- Quarter-end cash position: $472.2 million
- Net cash used in operations: $47.8 million in Q4, $150.3 million for full year
- 2025 cash guidance: Expected net cash use of $168-175 million
Notable developments include:
- Topline results expected in Q2 2025 from Phase 3 AFFIRM-AL trial of birtamimab
- Multiple clinical readouts for PRX012 starting mid-2025
- Received $80 million from Bristol Myers Squibb for PRX019 license
- Phase 2b PADOVA study results for prasinezumab in Parkinson's disease
Prothena (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on protein dysregulation expertise, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 20, 2025, after U.S. market close. The company will host a live audio conference call at 4:30 PM ET on the same day.
The conference call will be accessible through the company's website at www.prothena.com under the Investors tab, with a replay available for at least 90 days. Participants can also join via dial-in at +1 (800) 715-9871 (U.S./Canada toll-free) or +1 (646) 307-1963 (international) using conference ID 9788564.